Pre-made Bimagrumab biosimilar ( Whole mAb, anti-ACVR2B therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-069
Anti-ACVR2B therapeutic antibody (Pre-made Bimagrumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-ACVR2B therapeutic antibody (Pre-made Bimagrumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||5nhr:HL:AB|
|99% SI Structure||5nhw:HL/5nh3:HL:IM/5ngv:HL|
|95-98% SI Structure||None|
|Conditions Active||Cachexia;Muscular atrophy;Type 2 diabetes mellitus|
|Conditions Discontinued||Inclusion body myositis|
|Development Tech||MorphoSys HuCAL Phage Display|